Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia
Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia
复制标题
DOI：
10.1016/s0029-7844(99)00565-7
复制
发表时间：
2000-03-01
影响因子：
7.2
通讯作者：
Halmesmäki, E
中科院分区：
文献类型：
--
作者：
Vuorela, P;Helske, S;Halmesmäki, E
目的：检测健康和并发症孕妇羊水中血管内皮生长因子(VEGF)的可溶性受体水平，并与低氧上调的促红细胞生成素(EPO)水平进行比较。方法：对35例孕2周(孕14-19周)和29例(孕29周)的正常妊娠妇女的羊水进行检测。用双抗体夹心酶联免疫吸附试验检测22例妊娠晚期子痫前期患者、11例有或不伴先兆子痫的糖尿病患者及14例胎儿生长受限患者血清中可溶性血管内皮生长因子受体-1(VEGFR-1)的水平。结果：正常妊娠早期血清可溶性VEGFR-1水平(中位数22 ng/mL，2.3~29.5 ng/mL)明显高于妊娠晚期(中位数13 ng/mL，范围0.5~32 ng/mL)；P<；0.05)。在妊娠晚期的先兆子痫妇女中，其水平高于健康对照组(中位数为20 ng/mL，范围10.5-37 ng/mL；P<；0.05)。妊娠晚期水平最低的是糖尿病妇女(中位数为11 ng/mL，范围为0.5-27 ng/mL)。在患有子痫前期和糖尿病的妇女中，可溶于AF的VEGFR-1水平仍然低于单纯子痫前期妇女(中位数为13，范围为6-32 ng/mL；P<；0.05)。FGR患者羊水中可溶性VEGFR-1水平(中位数19.5 ng/m L，范围5-40 ng/m L)与对照组比较差异无统计学意义。血清可溶性VEGFR-1水平与促红细胞生成素水平无相关性。胎盘组织培养上清液中可检测到可溶性VEGFR-1(中位数14 ng/m L，范围9-22 ng/m L)。结论：子痫前期患者胎盘组织中sVEGFR-1水平升高与其水平升高有关，且与另一低氧诱导因子促红细胞生成素无关。《妇科杂志》2000；95：353-7。(C)2000年由美国妇产科医师学会颁发。
Objective: To measure the levels of the soluble receptor for the potent angiogenic agent vascular endothelial growth factor (VEGF) in amniotic fluid (AF) in healthy and complicated pregnancies, and compare them with levels of erythropoietin, another factor upregulated by hypoxia.Methods: We assessed amniotic fluid from the second (n = 35, gestational weeks 14-19) and third (n = 29) trimesters of healthy women, and from the third trimesters of preeclamptic (n = 22) and diabetic women with (n = 11) or without preeclampsia (n = 34) and from women with fetal growth restriction (FGR) (n = 14) for soluble VEGF receptor-1 (VEGFR-1) by enzyme-linked immunosorbent assay.Results: In early normal pregnancy, AF-soluble VEGFR-1 levels were higher (median 22 ng/mL, range 2.3-29.5 ng/mL) than in the third trimester (median 13 ng/mL, range 0.5-32 ng/mL; P < .05). In preeclamptic women during the third trimester, levels were higher (median 20 ng/mL, range 10.5-37 ng/mL; P < .05) than healthy controls. The lowest third-trimester levels were in diabetic women (median 11 ng/mL, range 0.5-27 ng/mL). In women with preeclampsia and diabetes, AF-soluble VEGFR-1 levels remained lower (median 13, range 6-32 ng/mL; P < .05) than in women with preeclampsia alone. Amniotic fluid levels of soluble VEGFR-1 in women with FGR (median 19.5 ng/mL, range 5-40 ng/mL) did not statistically differ from those of controls. The AF levels of soluble VEGFR-1 did not correlate with those of erythropoietin. Soluble VEGFR-1 was clearly detectable (median 14 ng/mL, range 9-22 ng/mL) in culture media from placental biopsies (n = 20).Conclusion: Preeclampsia is associated with increased levels of soluble VEGFR-1, which are independent of erythropoietin, another hypoxia-inducible factor. (Obstet Gynecol 2000;95:353-7. (C) 2000 by The American College of Obstetricians and Gynecologists.).